Deals & Financing

Licensing, acquisitions, financings and clinical readouts that matter for China-originated assets and the buyers looking at them, each linked to the company announcement or trade-press source. Upfront and milestone amounts are listed separately, as disclosed.

Browse by type

Latest

43 items, newest first
Filter
Type
Companies

Pfizer in-licenses three preclinical in vivo CAR-T programs from Starna, with $330M upfront

$330M upfront
Licensing

Spruce splits Harbour-originated CRHX-101 into Adrenyx, targeting a first-half 2027 Nasdaq listing

$5M initial convertible note
NewCo

Marrow Therapeutics launches with $173M in Series A and B financing

$173M
Financing

FDA launches Global Reliance Disclosure Program to share redacted approval reviews with foreign regulators

No deal value
Regulatory

Johnson & Johnson to acquire Ollin Biosciences; lead asset is Innovent-originated IBI324

$2.2B upfront
M&A

Lilly agrees to acquire Calytrix Bio for up to $1.5B in cash; upfront not separately disclosed

Up to $1.5B cash
M&A

Seawolf Therapeutics debuts with $100M in financing and a Sanofi collaboration

$100M financing
FinancingLicensing

Sinotau-B (09941.HK) opens Hong Kong IPO; trading expected November 24

About HK$341M–$446M
Financing

Phrontline Biopharma raises about $40M in a Series A

About $40M
Financing

FDA Issues Complete Response Letter for Ivonescimab in EGFR-Mutated NSCLC After TKI Therapy

No deal value
Regulatory

China releases the 2026 NRDL and commercial innovative-drug list, effective January 1, 2027

No deal value
Regulatory

RemeGen amends its Vor Bio license to add RC298, with about $56M in upfront value

About $56M upfront
Licensing

Windward Bio lists on Nasdaq (WWB); IPO and concurrent Sanofi placement expected to raise $225M

About $225M expected
Financing

US Defense Department removes WuXi AppTec from the Section 1260H list, without ruling out relisting

No deal value
Regulatory

China's health and insurance authorities outline measures to improve hospital access to innovative drugs

No deal value
Regulatory

BRL Medicine completes another equity round, saying 2026 rounds now exceed RMB 700M

Two 2026 rounds, over RMB 700M combined
Financing

Alphana Therapeutics completes the first close of a $50M Series A

$50M Series A (first close)
Financing

Sino Biopharm grants Boehringer Ingelheim options on six preclinical ADC and T-cell engager programs

$358M upfront and near-term
Licensing

Hinova licenses VAV1 molecular glue degrader HP570 to Evommune (ex-Greater China)

$30M upfront + up to $1.07B milestones
Licensing

Minghui licenses Japan rights to subcutaneous IGF-1R antibody MHB018A to ASKA

$110M upfront + up to $330M milestones
Licensing

CStone partners with Kimia to lead Phase 1 of a DDR-pathway small molecule

Terms undisclosed
Licensing

FDA grants priority review to BeOne's zanubrutinib plus rituximab in first-line mantle cell lymphoma

No deal value
Regulatory

Boan Biotech licenses denosumab biosimilar BA6101 (60 mg) for Japan

Terms undisclosed
Licensing

Pelthos to combine with Castle Creek Biosciences (D-Fi)

5.2M shares + up to $300M milestones
M&A

Junshi doses first patient in Phase 3 of JS207 plus JS007 for first-line HCC

NCT07823348
Clinical

Hisun Pharma in-licenses Xuanjing Bio siRNA platform and RGN6669

RMB10M upfront
Licensing

NMPA converts Junshi toripalimab urothelial cancer indication to full approval

—
Regulatory

Alphamab doses first patient in Phase 3 of JSKN033 for cervical cancer

JSKN033-301
Clinical

Ferring agrees to acquire fertility biotech Gameto

Up to $1.3825B
M&A

Duality/BioNTech DYNASTY-Breast02 meets PFS primary endpoint

541 patients
Clinical

Baicheng Pharma and related party Zhiyao Technology form joint venture Hangzhou Baijing Bio

RMB20M registered capital
Joint venture

CSPC starts China phase 3 of B7-H3 ADC SYS6043 in first-line triple-negative breast cancer

Not disclosed
Clinical

HUTCHMED's ex-China licence of a KRAS-EGFR conjugate to GSK closes

$110M upfront
Licensing

Zelgen receives first $10M milestone payment from AbbVie for ZG006

$10M milestone
Milestone update

Sino Biopharm completes enrollment in phase 3 of TSLP antibody TQC2731 for nasal polyps

Not disclosed
Clinical

CSPC starts China phase 1 of SYH2083, a dual LFA-1/RASP eye drop for dry eye disease

Not disclosed
Clinical

Hansoh and Roche sign an ADC strategic collaboration and licence agreement

$400M upfront
Licensing

FDA grants accelerated approval to GSK's Jemperli for MSI-H/dMMR locally advanced rectal cancer

No deal value
Regulatory

Estuary Bio raises $103M to advance local AAV therapy for ADPKD

$103M total
Financing

AstraZeneca and insitro form a strategic collaboration in difficult-to-treat cardiometabolic disease

$40M upfront
Licensing

OMass Therapeutics raises a $310M Series C

$310M (GBP230M)
Financing

City Therapeutics prices upsized IPO at about $200M

About $200M
Financing

CSPC announces China IND for SYS6088, a PD-1/VEGFA/CTLA-4 trispecific

No deal value
Clinical

Annual tally

China innovative-drug out-licensing
YearDealsTotal valueUpfront payments, combined
202494$51.9B—
2025157$135.7B$7.0B

Data from DIA Global Forum, March 2026. Upfront payments were only about 5% of total value; the rest is paid only if development reaches agreed milestones, and much of it never will be.